China’s National Joint Procurement Office (NJPO) has issued a notice correcting the pricing of Pregabalin Oral Solution supplied by KBN-Zhejinag Pharmaceutical Co., Ltd. The revised price for the 473ml:9.46g*1(100ml) specification is set at 11.78 RMB, effective immediately.
Policy Breakdown
- Price Correction: The updated price reflects a more accurate valuation of the product within the centralized procurement framework.
- Product Details: The correction applies specifically to the oral solution formulation, with no changes to other entries in the national procurement supply list.
- Market Implications: The adjustment ensures competitive pricing for healthcare providers and patients, aligning with the program’s goal of cost efficiency.
Industry Impact
Pharmaceutical companies participating in the centralized procurement program are advised to review their pricing strategies to maintain competitiveness. The move underscores the NJPO’s commitment to transparency and accuracy in drug pricing.
Looking Ahead
Stakeholders should monitor future pricing adjustments and supply list updates to stay informed of changes impacting market dynamics and procurement strategies.-China Health Reform Pulse
Policy Source: https://www.smpaa.cn/gjsdcg/2025/04/10/16525.shtml